|Bid||435.00 x 0|
|Ask||435.15 x 0|
|Day's range||434.15 - 437.90|
|52-week range||331.70 - 456.30|
|Beta (5Y monthly)||0.33|
|PE ratio (TTM)||24.77|
|Forward dividend & yield||8.60 (1.98%)|
|Ex-dividend date||14 Aug 2020|
|1y target est||326.96|
Top Analyst Reports for JPMorgan, PayPal & Novo Nordisk
SNY vs. NVO: Which Stock Is the Better Value Option?
What happened Shares of Altimmune (NASDAQ: ALT) were down by 15% as of 3:27 p.m. EDT on Wednesday. The biotech announced before the market opened that it would present preclinical data for ALT-801 in treating nonalcoholic steatohepatitis (NASH) at the European Association for the Study of the Liver annual meeting on Aug.